EGFR inhibitor upregulates HER3 expression and enhances the efficacy of HER3 targeting patritumab deruxtecan (HER3-DXd)

被引：0
|
作者：
Yonesaka, Kimio [1 ]
Tanizaki, Junko [1 ]
Maenishi, Osamu [2 ]
Sakai, Kazuko [3 ]
Goto, Hiroki [4 ]
Kobayashi, Maki [4 ]
Yoshimoto, Ryoto [4 ]
Otsuka, Eri [4 ]
Okida, Hiroaki [4 ]
Funabashi, Masanori [4 ]
Hashimoto, Yuuri [5 ]
Hirotani, Kenji [5 ]
Kagari, Takashi [5 ]
Nishio, Kazuto [3 ]
Nakagawa, Kazuhiko [1 ]
机构：
[1] Kindai Univ, Dept Med Oncol, Fac Med, Higashiosaka, Osaka, Japan
[2] Kindai Univ, Dept Pathol, Fac Med, Higashiosaka, Osaka, Japan
[3] Kindai Univ, Dept Genome Biol, Fac Med, Higashiosaka, Osaka, Japan
[4] Daiichi Sankyo RD Novare Co Ltd, Tokyo, Japan
[5] Daiichi Sankyo Co Ltd, Tokyo, Japan
来源：
CANCER SCIENCE | 2022年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E14-6-4
引用
收藏
页码：896 / 896
页数：1
相关论文
共 50 条
  • [1] The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody- drug conjugate
    Komatsu, Nagiho
    Sato, Saori
    Muramatsu, Sumie
    Nakamura, Ryuichi
    Koyama, Kumiko
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [2] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
    Yu, H.
    Baik, C.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W.
    Yang, J. C.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S107
  • [3] Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
    Hayashi, Hidetoshi
    Yu, Helena A.
    Baik, Christina
    Gold, Kathryn
    Johnson, Melissa L.
    Koczywas, Marianna
    Murakami, Haruyasu
    Nishio, Makoto
    Steuer, Conor
    Su, Wu-Chou
    Yang, James C. H.
    Karam, Samer
    Qui, Zhenhao
    Qiu, Yang
    Chen, Shuquan
    Yu, Channing
    Janne, Pasi A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S318 - S318
  • [4] Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
    Koyama, Kumiko
    Ishikawa, Hirokazu
    Abe, Manabu
    Shiose, Yoshinobu
    Ueno, Suguru
    Qiu, Yang
    Nakamaru, Kenji
    Murakami, Masato
    [J]. PLOS ONE, 2022, 17 (05):
  • [5] EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Sakai, Kazuko
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Goto, Hiroki
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S296 - S296
  • [6] EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd
    Haikala, Heidi M.
    Lopez, Timothy
    Kohler, Jens
    Eser, Pinar O.
    Xu, Man
    Zeng, Qing
    Teceno, Tyler J.
    Ngo, Kenneth
    Zhao, Yutong
    Ivanova, Elena, V
    Bertram, Arrien A.
    Leeper, Brittaney A.
    Chambers, Emily S.
    Adeni, Anika E.
    Taus, Luke J.
    Kuraguchi, Mari
    Kirschmeier, Paul T.
    Yu, Channing
    Shiose, Yoshinobu
    Kamai, Yasuki
    Qiu, Yang
    Paweletz, Cloud P.
    Gokhale, Prafulla C.
    Janne, Pasi A.
    [J]. CANCER RESEARCH, 2022, 82 (01) : 130 - 141
  • [7] Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).
    Yonesaka, Kimio
    Tanizaki, Junko
    Maenishi, Osamu
    Haratani, Koji
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Chiba, Yasutaka
    Goto, Hiroki
    Otsuka, Eri
    Okida, Hiroaki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines
    Hwang, Hae Min
    Kim, So Hyeon
    Ham, Sujin
    Lee, Minyoung
    Noh, Youlim
    Kim, Yu-Jin
    Lee, Changyun
    Kim, Jinyoung
    Lee, Dae-Won
    Lee, Kyung-Hun
    Im, Seock-Ah
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [9] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
    Janne, Pasi A.
    Baik, Christina
    Su, Wu-Chou
    Johnson, Melissa L.
    Hayashi, Hidetoshi
    Nishio, Makoto
    Kim, Dong-Wan
    Koczywas, Marianna
    Gold, Kathryn A.
    Steuer, Conor E.
    Murakami, Haruyasu
    Yang, James Chih-Hsin
    Kim, Sang-We
    Vigliotti, Michele
    Shi, Rong
    Qi, Zhenhao
    Qiu, Yang
    Zhao, Lihui
    Sternberg, David
    Yu, Channing
    Yu, Helena A.
    [J]. CANCER DISCOVERY, 2022, 12 (01) : 74 - 89
  • [10] HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
    Yonesaka, Kimio
    Tanizak, Junko
    Maenishi, Osamu
    Haratani, Koji
    Kawakami, Hisato
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Sakai, Kazuko
    Chiba, Yasutaka
    Tsuya, Asuka
    Goto, Hiroki
    Otsuka, Eri
    Okida, Hiroaki
    Kobayashi, Maki
    Yoshimoto, Ryoto
    Funabashi, Masanori
    Hashimoto, Yuuri
    Hirotani, Kenji
    Kagari, Takashi
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (02) : 390 - 403
12345